Niveles séricos de hormona antimulleriana como predictor de baja respuesta en mujeres sometidas a ciclos de fecundación in vitro

Delgado-García, Silvia; Eleno-Buendicho, Irene; Matallín-Evangelio, Pilar; Oliver-Sánchez, Cecilia; Oliva-García, Ana Belén; Mauri-Dot, Montse; Alfayate-Guerra, Rocío

doi:10.1016/j.medre.2014.12.002

Cited by 2 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to clinical experts and the published literature ( Slof, 2010 ), these doses are most commonly used in women of advanced maternal age (mean age 38 years). Other studies undertaken in Spain, in other European countries and in the United States of America also report using a daily dose of 300 IU rFSH for all days of controlled ovarian stimulation ( Berkkanoglu and Ozgur, 2010 , Delgado-García et al, 2015 , Drakopoulos et al, 2017 , Gleicher et al, 2015 , Naether et al, 2015 , Revelli et al, 2015 , Rubio et al, 2017 , Ubaldi et al, 2016 ), or during the additional days of controlled ovarian stimulation after administering 150 μg corifollitropin alfa on the first day ( Nielsen et al, 2016 , Polyzos et al, 2013a , Polyzos et al, 2013b ).…”

Section: Discussionmentioning

confidence: 99%

Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study

Barrenetxea¹,

García-Velasco²,

Aragón³

et al. 2018

Reproductive Biomedicine & Society Online

View full text Add to dashboard Cite

This study presents an economic assessment of controlled ovarian stimulation in assisted reproductive technology procedures in Spain, comparing the use of corifollitropin alfa and various forms of recombinant follicle-stimulating hormone (rFSH) in women of advanced maternal age. A cost-minimization analysis (CMA) was performed to assess the cost per cycle of controlled controlled ovarian stimulation, including only direct costs associated with the stimulation phase. The CMA was based on the population characteristics, the protocol, and the results obtained from the PURSUE study, taking into account 9 days of controlled controlled ovarian stimulation and 300 IU rFSH/day. The primary analysis included pharmacological costs alone. Different scenarios were evaluated including various doses and possible additional days (0–5) for rFSH. For the alternative analyses, the total costs (direct pharmacological costs, costs of visits and follow-up tests, and any additional pharmacological costs) were considered in both the private and public sectors. Treatment with corifollitropin alfa resulted in a lower pharmacological cost compared with rFSH (€757.25 and €950.30, respectively), creating a saving of approximately -20%. The results of the scenario analyses showed that corifollitropin alfa reduced the pharmacological cost of controlled ovarian stimulation in comparison with daily administration of doses ≥ 250 IU rFSH (considering same daily dose for all days), regardless of the additional days required (7–12 days) (average -€223; range -€488 to -€44). In conclusion, in addition to the efficacy shown in the PURSUE study, the use of corifollitropin alfa results in a decrease in the direct costs associated with controlled ovarian stimulation in older women in Spain.

show abstract